adg126
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 20, 2020 (NCT04645069)
Timeline
Indications
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314754 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06846268 | Phase 2 | Mar 1, 2025 | Adagene Inc, National University of Singapore |
| NCT05405595 | Phase 1 | Jun 15, 2022 | Adagene Inc, Merck |
| NCT04645069 | Phase 1 | Dec 20, 2020 | Adagene Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adagene Inc | For profit | 3 | 2 | 2 | 2020 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1